Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBT Margin of 633.49% for Q1 2026, up 4134.0% year-over-year from 14.96% in Q1 2025, and down 58.09% quarter-over-quarter from 400.72% in Q4 2025.
Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of EBT Margin data on file, last reported at 633.49% in Q1 2026.
- EBT Margin for Q1 2026 came in at 633.49%, up 4134.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 597.53% (up 49376.0% YoY), and the FY2025 annual result was 608.53%, up 23197.0% from the prior year.
- EBT Margin declined to 633.49% in Q1 2026 per NTLA's latest filing, from 400.72% in the prior quarter.
- Over five years, EBT Margin peaked at 6647.52% in Q4 2023 and troughed at 1820.05% in Q2 2024.
- A 5-year average of 431.25% and a median of 771.63% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2024: EBT Margin jumped 2310050 bps in 2022, then slumped 762481 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 771.63% in 2022, then surged by 961 bps to 6647.52% in 2023, then plunged by 115 bps to 977.29% in 2024, then surged by 59 bps to 400.72% in 2025, then plunged by 58 bps to 633.49% in 2026.
- Business Quant data shows NTLA's EBT Margin at 633.49% in Q1 2026, 400.72% in Q4 2025, and 760.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -633.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -633.49% |
| Dec 31, 2025 | -400.72% |
| Sep 30, 2025 | -760.14% |
| Jun 30, 2025 | -720.21% |
| Mar 31, 2025 | -674.83% |
| Dec 31, 2024 | -977.29% |
| Sep 30, 2024 | -1,455.91% |
| Jun 30, 2024 | -1,820.05% |
| Mar 31, 2024 | -350.34% |
| Dec 31, 2023 | 6,647.52% |
| Sep 30, 2023 | -987.05% |
| Jun 30, 2023 | -880.40% |
| Mar 31, 2023 | -793.10% |
| Dec 31, 2022 | -771.63% |
| Sep 30, 2022 | -780.83% |
| Jun 30, 2022 | -695.64% |
| Mar 31, 2022 | -1,277.16% |
| Dec 31, 2021 | -621.69% |
| Sep 30, 2021 | -23,881.33% |
| Jun 30, 2021 | -1,050.47% |